In Silico Discovery Meets Empirical Discovery
We explore our proprietary 1859 virtual library for a specific disease target and then design focused libraries of small molecules predicted to affect that target in a desired way.
We construct the focused libraries of small molecules for testing in a matter of weeks.
We screen focused libraries in a biochemical or cell based context at the pico-scale, with a few milliliters of materials.
We discover the identity of the molecules that affected the disease target, and then leverage machine learning and AI to design new focused libraries predicted to produce even better discoveries.
We offer the ability to navigate chemical space unimpeded by the capital and time constraints of the status quo, giving our partners access to the right type of chemical matter from the start of a discovery program. We use both structure-based and ligand-based virtual screening methods to identify the right properties of the molecules needed to affect a particular disease target. Lastly, we offer the ability to screen our growing inventory of Training Set Libraries designed to tease out the types of molecules we should include in a subsequent library design.
Molecules per Week Screened
for New Library Build
of Material per Screen
We are giving major pharmaceutical
partners unprecedented capabilities.
“…we are enthusiastic about the potential for 1859’s technology to enable miniaturized cell-based assays, ultra-high throughput screening, and rapid exploration of chemical space. The 1859 team has proven to be excellent partners.”—Confidential Top 25 Pharma Partner
We are opening up our technology and capabilities to partners looking to join our revolution on upending the current paradigm for new medicine discovery.Let's Partner
We are building the tools that will make the discovery of new medicines a data science.Join Us
Our Blog –
1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale
1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale to discover new small molecule medicines for emerging disease targets, launched today and announced the close of a highly successful Series A funding round of $40 million led by…